STOCK TITAN

Vycor Medical Q3 2026 revenue falls 19% to $415K

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Vycor Medical, Inc. (VYCO) reported revenue of $414,895 for the three months ended September 30, 2026, down 19% from 2025, and $1,291,699 for the nine months, down 11%. The ViewSite Brain Access System business generated quarterly revenue of $402,048, down 18%, and nine-month revenue of $1,243,713, down 11%. Gross profit was $353,017 for the quarter, down 22%, and $1,072,615 for nine months, down 12%. NovaVision revenue was $12,847 and $47,986, respectively; the business remains in development.

GAAP operating profit was $27,424 for the quarter, compared with $32,085, and $80,083 for nine months, compared with $70,425. Non-GAAP operating profit was $43,011 and $125,751, versus $60,162 and $166,262; the non-GAAP measures exclude depreciation and non-cash stock compensation. Net loss available to common stockholders was $161,447 for the quarter and $325,812 for nine months. Four new peer-reviewed VBAS studies were published during 2026 to date, bringing the total to 54, alongside 14 other clinical papers.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 4 points

How the balance works

Positive

  • Moderate pointNine-month GAAP operating profit was $80,083, versus $70,425.

Negative

  • Moderate pointQuarterly revenue fell 19% to $414,895.
  • Moderate pointQuarterly non-GAAP operating profit was $43,011, versus $60,162.
  • Minor pointNine-month revenue fell 11% to $1,291,699.
  • Minor pointNine-month non-GAAP operating profit was $125,751, versus $166,262.

Filing Explained

For the quarter, Vycor reported net income of $738 and $162,185 in preferred-stock dividends, leaving a $161,447 net loss available to common stockholders; that common-shareholder result reflects the preferred-dividend allocation despite positive consolidated net income.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Quarterly revenue $414,895 Three months ended September 30, 2026; down 19% from 2025
Nine-month revenue $1,291,699 Nine months ended September 30, 2026; down 11% from 2025
Quarterly gross profit $353,017 Three months ended September 30, 2026; down 22% from 2025
Nine-month gross profit $1,072,615 Nine months ended September 30, 2026; down 12% from 2025
Quarterly GAAP operating profit $27,424 Three months ended September 30, 2026; compared with $32,085 in 2025
Nine-month GAAP operating profit $80,083 Nine months ended September 30, 2026; compared with $70,425 in 2025
Quarterly non-GAAP operating profit $43,011 Three months ended September 30, 2026; compared with $60,162 in 2025
Nine-month non-GAAP operating profit $125,751 Nine months ended September 30, 2026; compared with $166,262 in 2025
non-GAAP Cash Operating Expenses financial
"non-GAAP Cash Operating Expenses of $310,006"
Operating costs measured on a cash basis after removing non-cash accounting charges and other items companies choose to exclude from standard financial statements. It typically starts with GAAP operating expenses and subtracts non-cash items such as depreciation, amortization, stock‑based compensation and impairments (and sometimes adds or excludes one‑time charges), so it aims to show the actual cash spent running the business. Investors use it as a way to see recurring cash outflows for operations, like checking the money that really leaves the bank to keep the business running.
non-GAAP Operating Profit financial
"non-GAAP Operating Profit was $43,011"
Non-GAAP operating profit is a company’s operating earnings after removing or adjusting items that management considers unusual, one-time, or not part of regular operations (for example, restructuring costs or stock-based pay). Investors use it like a cleaned-up scorecard to see the company’s core business performance without temporary noise, but because the adjustments aren’t standardized, it’s best compared across peers with caution.
stock-based compensation financial
"non-cash stock-based compensation"
Stock-based compensation is when a company pays employees, directors or consultants with shares or the right to buy shares instead of or in addition to cash. It matters to investors because issuing stock or options spreads ownership thinner (like cutting a pie into more slices), which can reduce each existing share’s claim on profits and can also change reported earnings; investors watch it to assess true cost of running the business and how management is incentivized.
posterior fossa metastases medical
"resection of previously untreated posterior fossa metastases"
tubular retractor medical
"outcomes of surgery using VBAS with traditional or so-called blade retractors"
cerebrospinal fluid diversion rates medical
"low cerebrospinal fluid diversion rates"
Revenue, three months $414,895 Down 19% from 2025
Revenue, nine months $1,291,699 Down 11% from 2025
GAAP operating profit, three months $27,424 Compared with $32,085 in 2025
GAAP operating profit, nine months $80,083 Compared with $70,425 in 2025
Non-GAAP operating profit, three months $43,011 Compared with $60,162 in 2025
Non-GAAP operating profit, nine months $125,751 Compared with $166,262 in 2025

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was VYCO's revenue in the third quarter of 2026?

Vycor Medical reported revenue of $414,895 for the three months ended September 30, 2026, down 19% from 2025. The ViewSite Brain Access System business generated $402,048, down 18%; NovaVision generated $12,847, up 41%.

What were VYCO's operating profit and net loss for the first nine months of 2026?

For the nine months ended September 30, 2026, GAAP operating profit was $80,083 and net loss available to common stockholders was $325,812. Non-GAAP operating profit was $125,751 and non-GAAP net loss available to common stockholders was $280,144; the non-GAAP measures exclude depreciation and non-cash stock compensation.

What did the 23-patient VBAS study compare?

The retrospective study compared tumor-resection outcomes using VBAS with traditional blade retractors. The release says the study reported significantly fewer new neurological deficits at follow-up for the tubular-retractor group.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001424768 0001424768 2026-11-13 2026-11-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): November 13, 2026

 

Vycor Medical, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware   001-34932   20-3369218

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File No.)

 

(I.R.S. Employer

Identification No.)

 

951 Broken Sound Parkway, Suite 320, Boca Raton, FL   33487
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (561) 558-2020

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock   VYCO   OTCQB

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

TABLE OF CONTENTS

 

Item 2.02. Results of Operations and Financial Conditions 3
Item 9.01 Financial Statements and Exhibits 3
SIGNATURES 4

 

2
 

 

Item 2.02. Results of Operations and Financial Conditions

 

The information in this report and the exhibit attached hereto are being furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall they be deemed incorporated by reference in any filing with the Securities and Exchange Commission under the Securities Act of 1934 or the Securities Act of 1933, except as shall be expressly set forth by specific reference to such filing.

 

On November 13, 2026, we issued a press release regarding our financial results for the three and nine months ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

 

Non-GAAP Measures

 

We make reference to non-GAAP financial information in this press release together with a reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures. Specifically, we have provided non-GAAP Cash Operating Expenses and non-GAAP Cash Operating Loss measures that exclude Depreciation and non-cash Stock Compensation.

 

We believe that these non-GAAP financial measures provide investors with insight into what is used by management to conduct a more meaningful and consistent comparison of our ongoing operating results and trends, compared with historical results. This presentation is also consistent with the measures management uses to measure the performance of ongoing operating results against prior periods and against our internally developed targets. There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the Company’s consolidated financial statements prepared in accordance with GAAP and the reconciliation of non-GAAP financial measures in this press release.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit 99.1.   Vycor Medical, Inc. Press Release dated November 13, 2026.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

3
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Vycor Medical, Inc.  
     
By: /s/ Peter C. Zachariou  
Name: Peter C. Zachariou  
Title: Chief Executive Officer  
     
Dated: November 16, 2026  

 

4

 

Exhibit 99.1

 

 

Vycor Medical Releases Financial Results for the Three And Nine Months Ended September 30, 2026

 

BOCA RATON, FL (November 13, 2026) – Vycor Medical, Inc. (“Vycor”) (OTCQB—VYCO), today announced financial results for the three and nine months ended September 30, 2026.

 

The Company operates through two business units: Vycor Medical, which produces the ViewSite™ Brain Access System (VBAS) for neurosurgeons; and NovaVision®, a business in development which offers therapy programs to help patients recover from visual disorders after stroke or other brain injury.

 

Company Highlights

 

  ● The Vycor Medical division revenues for the three months ended September 30, 2026 decreased by 18% and for the nine months ended September 30, 2026 reveneus decreased by 11%. Vycor experienced higher than normal US sales during the 2025 period from new hospitals and bulk orders from some existing hospitals which largely accounts for the decrease, offset by increased international sales for the three month period and a slight decrease over the nine months; international sales can often be lumpy with large orders sometimes falling in different quarters.
     
  ● Operating profit for the three months ended September 30, 2026 and 2025 was $27,424 and $32,085 respectively, and operating profit for the nine months ended September 30, 2026 and 2025 was $80,083 and $70,425 respectively.
     
  ● Non-GAAP operating profit for the three months was $43,011 compared to $60,162 in the 2025 period and for the nine months was $125,751 compared to $166,262 in the 2025 period.
     
  ● During 2026 to date, four new peer-reviewed studies were published on the ViewSite Brain Access System (VBAS), bringing the total published peer reviewed clinical papers to 54, with an additional 14 other clinical papers. One was a case study on a complex pediatric tumor case, which particularly highlighted the effectiveness of integrating neuro-navigation systems with VBAS as “a paramount strategy for the surgical resection” of this type of lesion. The second was a retrospective study of 23 patients undergoing tumor resection, comparing outcomes of surgery using VBAS with outcomes using traditional or so-called blade retractors. The study highlighted the significantly fewer new neurological deficits at follow up for the tubular retractor group compared to the traditional blade retractor group, implying safer tumor resection using VBAS. The third paper reported on a retrospective single-center study of 29 consecutive adults undergoing minimally invasive suboccipital tubular resection using VBAS of previously untreated posterior fossa metastases; the study conclusion was that minimally invasive tubular resection enables effective decompression of relatively large posterior fossa metastases with low cerebrospinal fluid diversion rates. The most recent paper reported on two patient cases of intracerebral hemorrhage (ICH) evacuation in Japan using VBAS with an exoscope and highlighted how VBAS was able to provide a stable corridor with sufficient visualization and working space to achieve deep hemostasis using familiar microsurgical instruments.

 

 
 

 

Financial Results

 

For the three months ended September 30, 2026, the Company reported revenue of $414,895, a decrease of 19% over the 2025 period. The Vycor Medical division (VBAS) generated revenue of $402,048, a decrease of $90,054 (or 18%) over the 2025 period. Gross profit for 2026 was $353,017, a 22% decrease over 2025, generating a margin of 85% and 88%, respectively. The NovaVision division, which remains in development, generated revenues of $12,847 for the three months ended September 30, 2026, a 41% increase over the 2025 period.

 

For the nine months ended September 30, 2026, the Company reported revenue of $1,291,699, a decrease of 11% over the 2025 period. The Vycor Medical division (VBAS) generated revenue of $1,243,713, a decrease of $148,697 (or 11%) over the 2025 period. Gross profit for 2026 was $1,072,615, a 12% decrease over 2025, generating a margin of 83% and 85%, respectively. The NovaVision division, which remains in development, generated revenues of $47,986 for the nine months ended September 30, 2026, an 11% increase over the 2025 period.

 

  

Three months ended

September 30,

  

Nine months ended

September 30,

 
   2026   2025   2026   2025 
Revenue                    
Vycor Medical  $402,048   $492,102   $1,243,713   $1,392,410 
NovaVision   12,847    21,690   $47,986   $54,113 
   $414,895   $513,792   $1,291,699   $1,446,523 
Gross Profit                    
Vycor Medical  $341,178   $431,227   $1,027,443   $1,174,808 
NovaVision   11,839    20,705   $45,172   $50,929 
   $353,017   $451,932   $1,072,615   $1,225,737 

 

For the three months ended September 30, 2026 the Company reported non-GAAP Cash Operating Expenses of $310,006 compared to $391,770 in the 2025 period, and non-GAAP Operating Profit of $43,011 compared to $60,162 in the 2025 period. For the nine months ended September 30, 2026 the Company reported non-GAAP Cash Operating Expenses of $946,864 compared to $1,059,475 in the 2025 period, and non-GAAP Operating Profit of $125,751 compared to $166,262 in the 2025 period.

 

Reconciliation of Non-GAAP Information

 

Non-GAAP Reconciliation

 

Management uses certain non-GAAP financial measures (including non-GAAP operating expenses and non-GAAP net loss and loss per share), which exclude non-cash depreciation of purchased assets and non-cash stock-based compensation. Management does not consider these costs in evaluating the continuing operations of the Company. Therefore, management calculates the non-GAAP financial measures provided in this earnings release excluding these costs and uses these non-GAAP financial measures to enable it to analyze further, and more consistently, the period-to-period financial performance of its core business operations. Management believes that providing investors with these non-GAAP measures gives them additional important information to enable them to assess, in the same way management assesses, the Company’s current and future continuing operations. There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the Company’s consolidated financial statements prepared in accordance with GAAP. Set forth below are reconciliations of the non-GAAP financial measures to the comparable GAAP financial measures.

 

 
 

 

Three months ended September 30, 2026

 

On a GAAP basis for three months ended September 30, 2026 the Company reported Operating Expenses of $325,593, an operating profit of $27,424, and a net loss of $(161,447) or $(0.00) per share.

 

Vycor’s GAAP operating costs for three months ended September 30, 2026 include non-cash depreciation of purchased assets ($15,587). The Company is providing additional non-GAAP financial measures that exclude these charges and expenses, and reconciliation of GAAP to non-GAAP results is provided in the tables included in this release.

 

On a non-GAAP basis, taking into account these adjustments, operating expenses for the three months ended September 30, 2026 were $310,006, non-GAAP operating profit was $43,011, and non-GAAP net loss was $(145,860) or $(0.00) per share.

 

Nine months ended September 30, 2026

 

On a GAAP basis for nine months ended September 30, 2026 the Company reported Operating Expenses of $992,532, an operating profit of $80,083, and a net loss of $(325,812) or $(0.01) per share.

 

Vycor’s GAAP operating costs for nine months ended September 30, 2026 include non-cash depreciation of purchased assets ($45,668). The Company is providing additional non-GAAP financial measures that exclude these charges and expenses, and reconciliation of GAAP to non-GAAP results is provided in the tables included in this release.

 

On a non-GAAP basis, taking into account these adjustments, operating expenses for the nine months ended September 30, 2026 were $946,864, non-GAAP operating profit was $125,751, and non-GAAP net loss was $(280,144) or $(0.01) per share.

 

 
 

 

VYCOR MEDICAL, INC.
Consolidated Statements of Comprehensive Loss
(audited)

 

`  For the three months ended September, 30   For the nine months ended September, 30 
   2026   2025   2026   2025 
                 
Revenue  $414,895   $513,792   $1,291,699   $1,446,523 
Cost of Goods Sold   61,878    61,860    219,084    220,786 
Gross Profit   353,017    451,932    1,072,615    1,225,737 
                     
Operating Expenses:                    
Research and development   -    -    -    9,963 
Depreciation and amortization   14,880    14,880    43,743    44,641 
Selling, general and administrative   310,713    404,967    948,789    1,100,708 
Total Operating Expenses   325,593    419,847    992,532    1,155,312 
Operating income   27,424    32,085    80,083    70,425 
                     
Other (Expense) Income                    
Interest expense: Related Party   (12,573)   (12,571)   (37,713)   (37,713)
Interest expense: Other   (13,386)   (13,884)   (39,789)   (39,885)
(Loss) gain on foreign currency exchange   56    (640)   (74)   (638)
Total Other (Expense)   (25,903)   (27,095)   (77,576)   (78,236)
                     
Income (Loss) Before Provision for Income Taxes   1,521    4,990    2,507    (7,811)
Provision for income taxes   -    -    -    - 
Net Income (Loss) from continuing operations   1,521    4,990    2,507    (7,811)
Loss from discontinued operations, net of tax   (783)   (54)   (3,949)   (1,929)
Net Income (Loss)   738    4,936    (1,442)   (9,740)
                     
Preferred stock dividends   (162,185)   (162,185)   (324,370)   (324,370)
Net Loss Available to Common Stockholders  $(161,447)  $(157,249)  $(325,812)  $(334,110)
                     
Other Comprehensive Income (Loss)                    
 Foreign Currency Translation Adjustment   -    -    20    - 
Comprehensive Income (Loss)  $738   $4,936   $(1,422)  $(9,740)
                     
Loss Per Share - basic and diluted                    
Loss from continuing operations  $(0.00)  $(0.00)  $(0.01)  $(0.01)
Loss from discontinued operations  $(0.00)  $(0.00)  $(0.00)  $(0.00)
Loss available to common stockholders  $(0.00)  $(0.00)  $(0.01)  $(0.01)
                     
Weighted Average Number of Shares Outstanding – Basic and Diluted   33,372,796    33,372,796    33,372,796    33,372,796 

 

 
 

 

VYCOR MEDICAL, INC.
Non-GAAP Reconciliation of Operating Loss and Net Loss
(unaudited)

 

   For the three months ended   For the nine months ended 
   September 30,   September 30, 
   2026   2025   2026   2025 
                 
GAAP Operating Expenses  $325,593   $419,847   $992,532   $1,155,312 
                     
Non-cash depreciation of purchased assets (1)   (15,587)   (15,868)   (45,668)   (46,999)
Non-cash stock-based compensation (2)   -    (12,209)   -    (48,838)
Total Non-GAAP Operating Expense Adjustments   (15,587)   (28,077)   (45,668)   (95,837)
                     
Non GAAP Cash Operating Expenses  $310,006   $391,770   $946,864   $1,059,475 
                     
GAAP Operating Profit  $27,424   $32,085   $80,083   $70,425 
                     
Non-GAAP Operating Expense Adjustments, as above   15,587    28,077    45,668    95,837 
                     
Non-GAAP Operating Profit  $43,011   $60,162   $125,751   $166,262 
                     
GAAP Net Income (Loss) available to common shareholders  $(161,447)  $(157,249)  $(325,812)  $(334,110)
                     
Non-GAAP Operating Expense Adjustments, as above   15,587    28,077    45,668    95,837 
                     
Non-GAAP Net Income (Loss) available to common stockholders  $(145,860)  $(129,172)  $(280,144)  $(238,273)
                     
Non-GAAP Income (Loss) Per Share basic and diluted  $(0.00)  $(0.00)  $(0.01)  $(0.01)
                     
Weighted Average Number of Shares Outstanding – Basic and Diluted   33,372,796    33,372,796    33,372,796    33,372,796 

 

(1) Non-Cash depreciation of purchased assets. These are non-cash charges related to assets which can be impacted by the timing and magnitude of acquisitions. We consider our operating results without these charges when evaluating our ongoing costs and performance and therefore exclude such charges when presenting non-GAAP financial measures.

 

(2) Non-Cash Stock-based compensation expense consists of expense relating to stock-based compensation issued to employees, outside directors and non-employees including stock options, restricted common stock, and warrants. Because of varying available valuation methodologies, subjective assumptions and the fact that these amounts vary in size and timing, we believe that the exclusion of stock-based compensation expense allows for a more accurate comparison of our financial results to previous periods. In addition, we believe it is useful to investors to understand the specific impact of stock-based compensation expenses on our operating results.

 

 
 

 

About Vycor Medical, Inc.

 

With corporate headquarters in Boca Raton, FL, Vycor Medical, Inc. (“Vycor”) is a publicly traded company (OTCQB: VYCO) dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions and has a growing portfolio of FDA cleared or registered medical solutions that are changing and improving lives every day. The Company operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach.

 

Vycor Medical’s FDA-cleared ViewSite™ Brain Access System (VBAS) a minimally invasive neurosurgical device designed to improve access to brain lesions while reducing tissue damage and enhancing patient outcomes. The VBAS system has been approved and used in over 350 hospitals in the US and in numerous countries internationally. VBAS is protected by 49 issued and 8 pending patents and has been validated through over 50 peer-reviewed studies. These studies demonstrate that use of VBAS results in: less brain tissue damage; less invasive procedure; improved access and better visibility; and reduced operating and recovery time. For an overview of Vycor Medical’s VBAS see VBAS Video.

 

NovaVision provides a suite of clinically supported vision rehabilitation therapies aimed at helping patients recover from visual impairments caused by stroke or other brain injury. The Visual Restoration Therapy (VRT) is the only commercialized FDA-cleared therapy for vision rehabilitation following neurological brain damage, making it a unique and important option for patients seeking to regain lost visual capabilities. The complementary NeuroEyeCoach program, clinically supported by a 296-patient study (the largest to date in the neuro visual space), enables dramatic improvements in patients’ ability to detect objects in the visual field by training them to make better eye movements with improvement in over 80% of patients. The NovaVision therapies, while showing a positive impact on these patients’ lives, still require significant development to allow them to successfully address their market potential. For an overview of NovaVision see NovaVision Video.

 

For the latest information on the company, including media and other coverage, and to learn more, please go online at www.vycormedical.com, www.vycorvbas.com or www.novavision.com.

 

Safe Harbor Statement

 

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “forecast”, “anticipate”, “estimate”, “project”, “intend”, “expect”, “should”, “believe”, and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Vycor Medical’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Vycor Medical’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Vycor Medical herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Vycor Medical disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

 

Vycor Medical, Inc. Contacts:

 

951 Broken Sound Parkway, Suite 320

Boca Raton, FL. 33487

(561) 558-2020

info@vycormedical.com

 

LinkedIn: https://www.linkedin.com/in/vycor-medical-inc/

Instagram: https://www.instagram.com/vycormedical/

Facebook: https://www.facebook.com/Vycor.Nova/

Twitter/X: https://x.com/vycormedical

YouTube: https://www.youtube.com/@vycormedical6049

 

##END##

 

 

 

Filing Exhibits & Attachments

5 documents

Keep reading